Log in

Sonoma Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:SNOA)

$5.92
+0.12 (+2.07 %)
(As of 11/12/2019 04:16 AM ET)
Today's Range
$5.92
Now: $5.92
$5.92
50-Day Range
$4.96
MA: $5.65
$6.80
52-Week Range
$4.85
Now: $5.92
$20.34
Volume2 shs
Average Volume11,069 shs
Market Capitalization$7.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNOA
CUSIPN/A
Phone707-283-0550

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.97 million
Book Value$7.89 per share

Profitability

Net Income$-11,800,000.00

Miscellaneous

Employees78
Market Cap$7.87 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.


Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) issued its quarterly earnings data on Tuesday, August, 13th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.79) by $2.33. The firm earned $4.71 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 39.48% and a negative return on equity of 66.14%. View Sonoma Pharmaceuticals' Earnings History.

When is Sonoma Pharmaceuticals' next earnings date?

Sonoma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Sonoma Pharmaceuticals.

Has Sonoma Pharmaceuticals been receiving favorable news coverage?

Media stories about SNOA stock have been trending very negative on Tuesday, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sonoma Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Sonoma Pharmaceuticals.

Are investors shorting Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 22,400 shares, a decrease of 9.3% from the August 30th total of 24,700 shares. Based on an average daily volume of 6,100 shares, the days-to-cover ratio is presently 3.7 days. Currently, 1.8% of the company's stock are sold short. View Sonoma Pharmaceuticals' Current Options Chain.

Who are some of Sonoma Pharmaceuticals' key competitors?

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Who are Sonoma Pharmaceuticals' key executives?

Sonoma Pharmaceuticals' management team includes the folowing people:
  • Mr. Frederick J. Sandford, CEO, Interim CFO & Director (Age 58)
  • Mr. Marc Umscheid, Chief Operating Officer (Age 50)
  • Dr. Robert Northey, Exec. VP of R&D (Age 62)
  • Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 55)
  • Ms. Victoria Covel, Assistant Controller

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $5.92.

How big of a company is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals has a market capitalization of $7.87 million and generates $18.97 million in revenue each year. Sonoma Pharmaceuticals employs 78 workers across the globe.View Additional Information About Sonoma Pharmaceuticals.

What is Sonoma Pharmaceuticals' official website?

The official website for Sonoma Pharmaceuticals is http://www.sonomapharma.com/.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 1129 NORTH MCDOWELL BLVD., PETALUMA CA, 94954. The company can be reached via phone at 707-283-0550 or via email at [email protected]


MarketBeat Community Rating for Sonoma Pharmaceuticals (NASDAQ SNOA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNOA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel